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Abstract 
The initiation and progression of many human diseases are mediated by a complex 
interplay of genetic, epigenetic, and environmental factors. As all diseases begin with 
an imbalance at the cellular level, it is essential to understand how various types of 
molecular aberrations, metabolic changes, and environmental stressors function as 
switching points in essential communication networks. In recent years, peroxisomes 
have emerged as important intracellular hubs for redox-, lipid-, inflammatory-, and 
nucleic acid-mediated signaling pathways. In this review, we focus on how nature and 
nurture modulate peroxisome biogenesis and function in mammalian cells. First, we 
review emerging evidence that changes in peroxisome activity can be linked to the 
epigenetic regulation of cell function. Next, we outline how defects in peroxisome 
biogenesis may directly impact cellular pathways involved in the development of 
disease. In addition, we discuss how changes in the cellular microenvironment can 
modulate peroxisome biogenesis and function. Finally, given the importance of 
peroxisome function in multiple aspects of health, disease, and aging, we highlight the 
need for more research in this still understudied field. 
Keywords 





Throughout their lifetime, organisms are continually exposed to a multitude of genetic, 
biological, environmental, and behavioral risk factors governing disease susceptibility. 
To survive and flourish against such a backdrop, they have to react appropriately to new 
circumstances as they arise. Most, if not all, organisms have the ability to respond to 
internal and external stimuli with altered programs of gene expression. This temporally 
and spatially regulated process, often referred to as ‘epigenetic reprogramming’, is 
driven in large part by changes in chromatin structure (e.g., DNA methylation and 
histone modifications) and gene transcription levels (e.g., transcription factor regulation 
and RNA processing) [1]. In general, these changes are coordinated by a diverse array 
of signals related to cellular metabolic state (e.g., NAD+/NADH ratios, tricarboxylic 
acid (TCA)1 cycle intermediates, total and reduced glutathione concentrations, and 
acetyl-coenzyme A (acetyl-CoA) levels) [2]. Over recent decades, peroxisomes have 
emerged as key regulators in overall cellular lipid metabolism [3]. In addition, these 
organelles have been recognized as important intracellular hubs for redox-, lipid-, and 
inflammatory-mediated signaling pathways, and – very recently – as the primary sites 
that initiate type III interferon expression in response to viral and bacterial infections 
(see [4-6], and references therein). Despite these developments, the cause and effect 
relationships that exist between peroxisomal (dys)functions and epigenetic alterations 
are just starting to be explored. 
In the following sections, we first provide background information on the mechanisms 
by which cells integrate genetic and environmental stimuli and translate them into 
phenotypic outcomes. Next, we explore the link between genetic/environmental 
interactions and peroxisome biogenesis/function in mammalian cells. Finally, we 
highlight research directions designed to extend our knowledge in these areas. This is 
of paramount importance, given that peroxisomes play a pivotal role in human 
physiology and that effective therapeutic strategies for treatment of patients with 
peroxisomal deficiencies are still very much limited [7]. 
                                                 
1Abbreviations: 4-PBA, 4-phenylbutyrate; 5mC, 5-methylcytosine; -KG, α-
ketoglutarate; ABCD, ATP-binding cassette, subfamily D; ART, ADP-
ribosyltransferase; CoA, coenzyme A; DDM, DNA demethylase; DHA, 
docosahexaenoic acid; DNMT, DNA methyltransferase; ERT, enzyme replacement 
therapy; FAD, flavin adenine dinucleotide; FDA, United States Food and Drug 
Administration; GSH (reduced) glutathione; GSSG, oxidized glutathione; HAT, 
histone acetylase; HDAC, histone deacetylase; HDM, histone demethylase; HIF, 
hypoxia inducible factor; HMT, histone methyltransferase; JmjC, Jumonji C; IDH, 
isocitrate dehydrogenase; IRD, infantile Refsum disease; miR, microRNA; 
NAD(P)(H), (reduced) nicotinamide adenine dinucleotide (phosphate); NALD, 
neonatal adrenoleukodystrophy; ncRNA, non-coding RNA; PARP, poly(ADP-ribose) 
polymerase; PBD, peroxisome biogenesis disorder; PED, peroxisomal 
enzyme/transporter deficiency; PPAR, peroxisome proliferator-activated receptor; 
PPARGC1A, PPAR  coactivator 1; PTS1, C-terminal peroxisomal targeting signal; 
RCDP, rhizomelic chondrodysplasia punctata; ROS, reactive oxygen species; SAH, S-
adenosylhomocysteine; SAHA, suberoylanilide hydroxamic acid; SAM, S-
adenosylmethionine; RXR, retinoid X receptor; TCA, tricarboxylic acid; VLCFA, 
very-long-chain fatty acid; X-ALD, X-linked adrenoleukodystrophy; ZS, Zellweger 
syndrome; ZSD, Zellweger spectrum disorder. 
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2. Molecular mechanisms of epigenetics 
Epigenetic changes are a critically important mechanism by which the environment 
directly impacts gene expression without changing the underlying genomic sequence. 
As currently understood, these changes are brought about by DNA methylations, 
histone modifications, and non-coding RNA regulations [1]. In the following sections, 
we briefly outline epigenetic alterations that can be directly, or indirectly, linked to 
changes in peroxisomal function. 
2.1. DNA methylations 
DNA methylation is a process in which methyl groups are added to cytosine or adenine 
nucleotides in genomic DNA. In mammals, methylation typically takes place on 
cytosine residues immediately preceding guanine bases. As cytosine methylation both 
physically impedes transcription factor binding and attracts specific methyl-DNA 
binding proteins that subsequently recruit other chromatin remodeling proteins that can 
modify histones (e.g., histone deacetylases; see 2.2.2.), this process is, in general, 
associated with transcriptional repression [8]. DNA methylation is catalyzed by a 
family of S-adenosylmethionine (SAM)-dependent enzymes, called DNA 
methyltransferases (DNMTs), that transfer a methyl group from SAM to the 5-position 
of cytosine to form 5-methylcytosine (5mC), yielding S-adenosylhomocysteine (SAH) 
as a byproduct [9]. DNA demethylation can be achieved in both passive and active 
fashion. For example, as DNMT1 maintains methylation during DNA replication, its 
inhibition allows newly incorporated cytosine to remain unmethylated [9]. Active DNA 
demethylation in mammals is a complex multistep process that is controlled by DNA 
demethylases (DDMs) that belong to different protein families (e.g., TET, BER, and 
AID/APOBEC). For additional details regarding these enzymes and the chemical 
intermediates that are formed during the demethylation process, we refer the reader to 
Kohli and Zhang [10]. 
2.2. Histone modifications 
Histones are a family of basic proteins that package nuclear DNA into structural units, 
called nucleosomes. These proteins can undergo a wide variety of posttranslational 
modifications, including methylation, acetylation, ADP-ribosylation, phosphorylation, 
ubiquitination, and sumoylation. These and other modifications contribute to a precise 
regulation of gene expression by controlling chromatin conformation (e.g., through 
electrostatic and structural changes) and providing binding sites for non-histone DNA-
binding proteins such as transcription factors, transcriptional coactivators, and 
chromatin remodeling complexes [11]. As there is little evidence that links peroxisomes 
to histone phosphorylation, ubiquitination, and sumoylation, these modifications will 
not be considered further here. 
2.2.1. Histone methylations 
In mammals, there are different classes of histone methyltransferases (HMTs) and 
histone demethylases (HDMs) that control the methylation status of particular lysine 
and arginine residues in histones. The functional outcome of histone methylation 
strongly depends on the number of methyl groups that are added and the 
location/context of where they occur [8]. Like DNMTs, all HMTs use SAM as a 
cofactor and methyl donor and produce SAH as a byproduct. HDMs are classified into 
two distinct groups depending on their catalytic mechanism: lysine-specific 
demethylases, which are FAD-dependent amine oxidases; and demethylases containing 
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a Jumonji C domain (JmjC) that catalyze a dioxygenase reaction dependent on Fe2+ and 
-ketoglutarate (-KG) [12]. 
2.2.2. Histone acetylations 
Histones can be acetylated on specific lysine residues. This process neutralizes the basic 
charge of these residues, thereby promoting a general relaxation of chromatin structure 
and an induction of gene expression [8]. The acetylation status of histones is controlled 
by a dynamic interplay of histone acetylases (HATs) and histone deacetylases 
(HDACs). HATs require cytoplasmic acetyl-CoA as donor of the acetyl moiety and 
release free coenzyme A (CoA) [13]. HDACs yield free acetate that subsequently can 
be incorporated into acetyl-CoA by acetyl-CoA synthetases. HATs and HDACs are 
classified into multiple protein families, each having distinct opportunities for 
mechanistic regulation [8]. In the context of this review, it is important to mention that 
class I and class II HDACs (the non-sirtuin HDACs) share a catalytic mechanism that 
involves the coordination of a divalent metal ion, and class III HDACs (the sirtuins) are 
NAD+-dependent histone deacetylases whose activity is controlled by the cellular 
[NAD+]/[NADH] ratio. Note also that the activity of the non-sirtuin HDACs is 
influenced by the availability of metabolic intermediates such as free CoA, CoA-
derivatives, butyrate, and NADPH [14]. 
2.2.3. Histone ADP-ribosylation 
ADP-ribosylation is an important posttranslational modification in which one or more 
ADP-ribose moieties are added to a protein. The addition of ADP-ribosome units to 
histones is catalyzed by members of the poly(ADP-ribose) polymerase (PARP) protein 
family and occurs preferentially on glutamate or lysine residues [8]. This modification 
can affect gene expression at various levels (e.g., relaxation of chromatin structure, 
transcription factor binding, and mRNA processing). Importantly, all ADP-
ribosyltransferase (ART) family members consume NAD+ and release nicotinamide as 
a byproduct [8]; and excessive PARP activity may cause cell dysfunction (or even cell 
death) due to a depletion of NAD+ and the subsequent drop in ATP levels [8]. Mono- 
and poly(ADP-ribose) moieties can also be enzymatically removed from histones - for 
more details, see [15]. 
2.2.4. Regulatory non-coding RNAs 
The discovery that some classes of non-coding RNAs (ncRNAs) can also silence 
transcriptional activity has added an additional layer of complexity to how genes are 
expressed. The modes of action of these regulatory ncRNAs can vary depending on 
their size, structure and function. For example, long (>200 nucleotides) regulatory 
ncRNAs, which are often tissue-specifically expressed and involved in the long-term 
silencing of particular developmental control genes [8], can function as decoys, 
scaffolds, or guides for regulatory proteins and protein complexes [16]. Other 
regulatory ncRNAs such as microRNAs (miRs; ~21-22 nucleotides), and piwi-
interacting RNAs (24-30 nucleotides), can negatively impact gene expression by 
binding to the 3’-untranslated region of target mRNAs [1]. Importantly, regulatory 
ncRNAs have emerged as critical factors in cellular metabolism and development; 
altered expression of these molecules has been implicated in a number of diseases [1]. 
3. Cellular metabolism and epigenetics 
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As should be clear from the previous section, many of the enzymes involved in 
epigenetic regulation require intermediates of cellular metabolism to exert their 
function. This implies that these enzymes can function as metabolic sensors, and that 
fluctuations in cellular metabolic state (e.g., in response to normal or pathological 
stimuli) are likely to lead to changes in gene expression [17-21]. Examples of 
metabolites involved in such sensing mechanisms are listed in Table 1. Importantly, the 
regulation of epigenetic processes through metabolites involves multiple layers of 
complexity. For example, as members of the sirtuin and PARP families exert opposite 
effects on chromatin structure and gene regulation, a limited availability of NAD+ may 
lead to a direct competition between these different types of chromatin-altering 
enzymes. In addition, as NAD(P)+, FAD, and glutathione (or -glutamyl-cysteinyl-
glycine, a thiol-containing tripeptide that can exist in a reduced (GSH) or oxidized 
(GSSG) state) play an important role in maintenance of the cellular redox state, it is 
clear that epigenetic modifications are also affected by to oxidative stress. In this 
context, it is relevant to note that (i) redox changes can directly regulate HDAC 
activities, (ii) the activities of JmjC-HDMs and TET 5mC hydroxylases are controlled 
by oxygen tension, and (iii) Dicer, a central enzyme in miR processing, functions as an 
oxidative stress-responsive protein (see [8], and references therein). Epigenetic 
regulators may also employ different mechanisms for translating metabolic differences 
into distinct gene expression patterns. On one hand, they may directly modify genomic 
DNA and histones to regulate chromatin condensation. On the other hand, they may 
posttranslationally modify transcriptional regulators. Finally, it is important to note that 
epigenetic modifications also play a central role in the regulation of lipid and other 
metabolic pathways [17]. 
To regenerate their pool of GSH, cells have to either recycle GSSG to GSH with the 
help of an NADPH-dependent glutathione reductase (GR) or synthesize new GSH. The 
latter pathway is especially important under conditions of prolonged exposure to 
oxidative stress, in which NADPH stores become depleted and cells may lose GSH due 
to export of GSSG and GSH-adducts [8]. However, as (i) the rate-limiting substrate for 
de novo GSH biosynthesis is cysteine; (ii) the formation of this amino acid from 
methionine occurs via a series of reactions involving, among other intermediates, SAM 
and SAH; and (iii) SAM functions as a universal methyl donor for methyltransferases 
- de novo synthesis of GSH may very well have a major impact on epigenetic status 
[8,22]. 
4. Peroxisomes and epigenetics 
Peroxisomes harbor a complex set of enzymes that participate in diverse metabolic 
pathways, such as α- and -oxidation of fatty acids, detoxification of ROS, and 
biosynthesis of docosahexaenoic acid, bile acids, and ether-phospholipids [3,23,24]. As 
these processes generate a variety of intermediates and by-products that may potentially 
serve as substrates or inhibitors of multiple epigenetic regulators, it is very likely that 
these organelles participate in epigenetic signaling (Fig. 1). However, despite this 
potential connection, the precise role of peroxisomes in epigenetic programming 
remains a largely uncharted field. In the next sections, we outline how peroxisomal lipid 
and redox metabolism can potentially influence the levels of key metabolites that are 
important for a number of transcriptional and epigenetic processes. Then, we review 
how peroxisome (dys)function may influence the epigenetic landscape. 
4.1. Linking peroxisomal metabolism and epigenetics 
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4.1.1. Peroxisomal lipid metabolism 
A major function of peroxisomes is the breakdown of a select set of lipophilic 
carboxylic acids through α- and -oxidation pathways [3]. These processes involve a 
set of cosubstrates (e.g., FAD, NAD(P)+, O2, -KG) and metabolites (e.g., acetyl-CoA, 
succinate) that can potentially regulate the activity of epigenetic modifiers. For 
example, the first step (acetyl-CoA dehydrogenation) of peroxisomal -oxidation 
requires FAD-dependent oxidases that pass electrons to O2, thereby yielding H2O2; the 
second (2-enoyl-CoA hydration) and third (3-hydroxyacyl-CoA dehydrogenation) steps 
of this process are catalyzed by NAD+-dependent multifunctional proteins; and the final 
step (3-ketoacyl-CoA thiolysis), which is catalyzed by either acetyl-CoA 
acyltransferase or sterol-carrier-protein X (SCPx), results in the formation of acetyl-
CoA or propionyl-CoA [3]. Given that peroxisomes also contain a highly specific 
succinyl-CoA thioesterase, -oxidation of dicarboxylic acids may lead to the formation 
of succinate [25]. Note that succinate can also be produced by phytanoyl-CoA -
hydroxylase, a peroxisomal -oxidation enzyme that functions as a Fe2+-, α-KG-, and 
O2-dependent dioxygenase that hydroxylates phytanoyl-CoA at position 2 (thereby 
converting -KG into CO2 and succinate) [3]. 
Importantly, as epigenetic modifications are strongly influenced by metabolite 
availability, a conditio sine qua non to link peroxisomal lipid metabolism to such events 
is that relevant cosubstrates (e.g., NAD(P)+/NAD(P)H, α-KG) and metabolites (e.g., 
acetate/acetyl-CoA, succinate) can cross the peroxisomal membrane. As peroxisomes 
lack a citric acid cycle and respiratory chain, continued -oxidation requires free CoA, 
the reoxidation of NADH, the regeneration of NADPH, and the export of shortened 
substrates [24]. Most β-oxidation substrates are activated outside peroxisomes, and 
their CoA forms are subsequently translocated across the organelle membrane through 
ATP-binding cassette transporters of the D subfamily (ABCD) [3]. The shortened 
substrates (e.g., acetyl-CoA, propionyl-CoA, succinyl-CoA, and other acyl-CoAs) are 
enzymatically converted to their free acids (e.g., by acetyl-CoA thioesterases) or 
carnitine esters (e.g., by acyl-carnitine transferases), thereby releasing CoA inside 
peroxisomes [3]. This process not only prevents CoA trapping, but also provides an 
acyl-CoA thioesterase-dependent feedback mechanism to regulate the CoA and acetyl-
CoA levels inside the organelle [25]. The free acids and carnitine esters can then be 
used for fatty acid elongation or leave the organelle by transporters (e.g., OCTN3) or 
by passive diffusion through channels (e.g., PXMP2) [26]. CoA can be reused by 
peroxisomal thiolases or acetyl-CoA synthetases [27], or degraded by the peroxisomal 
Nudix hydrolases NUDT7 and NUDT19 (see [28], and references therein). In general, 
the peroxisomal membrane is considered to be impermeable to NAD(P)+ and 
NAD(P)H. The NADH produced inside peroxisomes is thought to reoxidize to NAD+ 
through lactate/pyruvate and glycerophosphate redox shuttles [26]. The 
intraperoxisomal reduction of NADP+ to NADPH is catalyzed by isocitrate 
dehydrogenase 1 (IDH1) and glucose-6-phoshate dehydrogenase, two enzymes that are 
located in multiple subcellular compartments [26]. The peroxisomal levels of NAD(P)+ 
and NAD(P)H are controlled by NUDT12, a peroxisomal Nudix NADH-diphosphatase 
[28], and SLC25A17 - a peroxisomal membrane protein that belongs to the family of 
mitochondrial solute carriers [29]. Note that the latter protein is not only thought to 
function as an NAD+ transporter, but also as a transporter of free CoA and FAD [29]. 
Finally, given the properties and exclusion limit (0.6 kDa) of the channel-forming 
protein PXMP2, small metabolic intermediates such as acetate, propionate, succinate, 
and -KG can be expected to freely diffuse across the peroxisomal membrane [26]. 
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However, note that the existence of a -KG/isocitrate transporter in the peroxisomal 
membrane has been reported [30]. 
4.1.2. Peroxisomal redox metabolism 
Over the years, it has become apparent that peroxisomes are central players in cellular 
redox metabolism [5]. They contain different sets of ROS-producing enzymes, of which 
the H2O2-generating FAD-linked oxidases (see 4.1.1.) represent the largest group. Also, 
the organelles are well equipped with a variety of antioxidant defense mechanisms, of 
which the H2O2-degrading enzyme catalase is perhaps the best characterized. So far, no 
consensus has emerged whether or not peroxisomes function as net sources, or sinks, 
of ROS. This most likely depends on the growth environment and (patho)physiological 
state of the cell. For example, an increase in peroxisomal fatty acid metabolism leads 
to an increase in peroxisomal H2O2 production (see [5], and references therein). The 
H2O2 generated in this process may be disposed by catalase or leak out into the cytosol 
[31]. Importantly, alterations in peroxisomal H2O2 metabolism have been shown to 
influence cellular GSH/GSSG balance and protein disulfide content [5]. Note that, as 
(i) NADPH is required for the GR-catalyzed regeneration of GSH from GSSG (see 
3.3.), and (ii) decreased NADPH/NADP+ ratios also affect NADH/NAD+ ratios due to 
the modulating capacity of NAD+ kinases on the equilibrium between NADPH/NADP+ 
and NADH/NAD+ ratios [20], a decrease in the GSH/GSSG ratio will rapidly increase 
the NAD+/NADH ratio. Like other small metabolites, GSH may freely penetrate the 
peroxisomal membrane through PXMP2 [26]. How GSSG is reduced in or exported out 
of the peroxisomal matrix, remains to be investigated. Finally, it is important to 
emphasize that peroxisome-derived ROS may influence epigenetic signaling through 
mechanisms other than affecting the levels of metabolites that control the activity of 
chromatin modifiers. Indeed, previous studies have revealed that changes in 
peroxisomal H2O2 metabolism can directly or indirectly modulate the activity of various 
transcription factors (e.g., NF-B, CREB1, and PPARGC1A) (see [5], and references 
therein). In addition, as (i) peroxisomal and mitochondrial metabolism are closely 
intertwined [5], and (ii) alterations in mitochondrial metabolism may heavily influence 
the epigenome [32] - it is very likely that changes in peroxisome activity also lead to 
epigenetic remodeling through alterations in mitochondrial function. 
4.2. Peroxisome (dys)function and epigenetics: a fairly unexplored twist 
As is evident from the material presented above, peroxisomal metabolism can be linked 
to metabolites that play a crucial role in epigenetic processes (Fig. 1). However, direct 
evidence that peroxisomes do indeed play a role in epigenetic programming under 
normal physiological conditions is lacking. Therefore, in the following sections, we 
focus on the (aberrant) epigenetic events that arise as a consequence of peroxisomal 
dysfunction. For clarity, we first provide background information about how defects in 
peroxisome biogenesis and function may impact human physiology. 
4.2.1. Compromised peroxisome function and disease 
Peroxisome biogenesis is mediated by proteins called peroxins – molecules localized 
variously to the organelle and cytosol. When these essential molecules are absent or 
non-functional, havoc can reign on the organelle, on the cell, and on the organism. 
Complex biochemical pathways are compromised, resulting in such metabolic errors as 
an accumulation of potentially toxic unprocessed fatty acids and an inability to 
synthesize essential docosahexaenoic acid, bile acids, and plasmalogens - among other 
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molecules. Typically, these alterations of metabolism manifest themselves in 
devastating phenotypes, with many human patients succumbing to the disease before 
age two [7]. The peripheral nervous system is often impacted, as are the brain, liver, 
kidneys, and eyes. These pathologies often translate into hypotonia, seizures, gliosis, 
hepatomegaly, neuronal demyelination, sensory deficits, and developmental delays [7]. 
At the molecular level, peroxisomal diseases can be classified into two groups: 
peroxisome biogenesis disorders (PBDs) and single enzyme/transporter deficiencies 
(PEDs). The former occur when an autosomal recessive mutation exists in one or more 
PEX genes (encoding peroxins). Mutations in 14 of the 16 PEX genes result in a PBD; 
there are no known diseases associated with PEX11α or PEX11γ mutations [7]. 
However, recent findings suggest that a PEX11α deficiency in mice is associated with 
aggravated interstitial renal lesions [33]. The PBDs encompass the Zellweger spectrum 
disorders (ZSDs) and rhizomelic chondrodysplasia punctata (RCDP) type 1. The ZSDs 
include, in order of decreasing clinical severity, Zellweger syndrome (ZS), neonatal 
adrenoleukodystrophy (NALD), and infantile Refsum disease (IRD). So far, no 
genotype-phenotype correlation has been found, and the phenotypic severity of this 
group of disorders is mainly determined by the residual activity of the mutated peroxin. 
RCDP type 1 is caused by mutations in PEX7, which encodes the receptor for proteins 
having an N-terminal peroxisomal targeting signal (PTS2). As hubs of cellular 
metabolism, peroxisomes contain more than 60 distinct enzyme constituents and 
metabolite transporters [34]. This alone sets the stage for many PEDs, which occur 
when one of these critical enzymes is dysfunctional or absent. These can be 
subclassified into different categories according to the peroxisomal function that is 
actually lost (e.g., fatty acid α-oxidation, fatty acid β-oxidation, ether-phospholipid 
biosynthesis, glyoxylate metabolism, or H2O2 metabolism) [35]. The severity of the 
disease depends on the enzyme involved, with a broad range of clinical manifestations 
possible [35]. 
Even when the peroxisomes assemble comprehensive machineries for protein 
trafficking and proper function, maladies may still arise. Indeed, a growing body of 
evidence supports the view that peroxisomes are key players in the etiology and 
progression of oxidative stress-related disorders [23]. Environmental factors that 
interfere with peroxisome biogenesis may compound such effects (for more details, see 
5.). 
4.2.2. Peroxisome dysfunction and changes in the epigenetic landscape 
4.2.2.1. DNA and histone (de)methylation 
As peroxisomes have the potential to directly or indirectly alter the levels of a number 
of metabolites that function as substrates for DNMTs, HMTs, and HDMs, changes (or 
defects) in peroxisome function can be expected to influence the activities of these 
chromatin-modifying enzymes. However, so far, this view is only supported by two 
pieces of indirect evidence. 
First, it has been shown that recurrent mutations in IDH1, a cytosolic and peroxisomal 
enzyme that catalyzes the oxidative decarboxylation of isocitrate to -KG (thereby 
reducing NADP+ to NADPH) [36], are associated with a hypermethylation phenotype 
in hematologic (e.g., acute myeloid leukemia) and solid (e.g., glioma, chondrosarcoma, 
and cholangiocarcinoma) tumor malignancies (see [37], and references therein). 
Interestingly, these mutations occur at a single amino acid residue (R132) within the 
active site of IDH1, and result in a protein that can no longer exert its wild-type activity 
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but rather has acquired the ability to convert -KG to the oncometabolite 2-
hydroxyglutarate, thereby using NADPH as a cofactor. As 2-hydroxyglutarate 
functions as a competitive inhibitor of α-KG-dependent dioxygenases (e.g., JmjC-
HDMs and TET 5mC hydroxylases) [38], this results in enhanced trimethylation of 
H3K9 and hypermethylation of CpG promoter regions [39,40]. Although the precise 
contribution of mutant peroxisomal IDH1 to cancer cell 2-hydroxyglutarate production 
remains to be established, it is quite likely that this pool of protein has the potential to 
affect the activity of chromatin-modifying enzymes (and hence the methylation status 
of chromatin). Relatedly, cartilage-specific IDH1R132Q knock-in mice and mice lacking 
PEX7, share a remarkable number of similar features, such as skeletal abnormalities, 
dwarfism, hypotonia, and high risk of death on the day of birth or prior to weaning [41]. 
Second, there is currently sufficient empirical evidence to argue that disturbances in 
peroxisome function affect cellular GSH levels (see [5], and references therein). As 
alterations in GSH homeostasis directly impact the glutathionylation state of histones 
as well as the de novo synthesis and availability of the universal methyl donor SAM 
(see 3.3.), it is reasonable to assume that changes in peroxisome activity may also 
influence DNA and histone methylation patterns. One argument in favor of this 
hypothesis is that polymorphisms in methionine metabolism genes have been described 
as possible disease modifiers in X-linked adrenoleukodystrophy (X-ALD) [42], a 
severe neurodegenerative disorder that is caused by defects in the peroxisomal ATP-
binding cassette transporter protein ABCD1 and characterized by, among other things, 
the accumulation of very-long-chain fatty acids (VLCFAs), oxidative stress, 
bioenergetic failure, and axonal degeneration (see [43], and references therein). 
However, do note that despite the fact that loss of ABCD1 function clearly influences 
gene expression in cultured dermal fibroblasts and induced pluripotent stem cells, the 
global DNA methylation profiles of X-ALD cells is apparently indistinguishable from 
that of control cells [44]. A second argument is that disturbances in peroxisomal redox 
metabolism have an immediate impact on mitochondrial ROS production (see [5], and 
references therein), an event that can be directly linked to a decrease in mitochondrial 
DNA methylation [45]. 
4.2.2.2. Histone (de)acetylation 
The enzymatic activities of HATs and HDACs, two classes of enzymes that control the 
acetylation state of histones, are tightly controlled by the nutritional, energetic, and 
redox state of a cell (see 2.2.2.). As many of these conditions are directly or indirectly 
influenced by changes in peroxisome activity (see 4.1.), it may not come as a surprise 
that malfunctioning of peroxisomes can be linked to changes in histone acetylation. For 
example, it has been shown that phytanic acid, a dietary fatty acid that is degraded via 
peroxisomal α-oxidation and best known for its accumulation in Refsum disease [3], 
enhances HDAC activity in vitro and reduces histone acetylation in Neuro2a cells, 
thereby inducing cell death [46]. In addition, it has been reported that sirtuin 1 (SIRT1), 
an NAD+-dependent protein deacetylase that links transcriptional regulation directly to 
intracellular energetics, is dysregulated in the spinal cords of 12-month-old Abcd1-/- 
mice as well as in the affected white matter of X-ALD patients [43]. Finally, as the 
acetyl-moieties resulting from peroxisomal β-oxidation can leave the organelle [25,35], 
it is very likely that peroxisomal metabolism can also influence HAT activity. This is 
perhaps best illustrated by the observation that peroxisome-derived acetyl-moieties can 
serve as substrate for acetyl-CoA carboxylase [25], a cytosolic enzyme that regulates 
global histone acetylation by controlling the availability of acetyl-CoA for HATs [47]. 
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Disturbances in peroxisomal metabolism may also result in a decrease of the 
intracellular acetyl-CoA and free CoA concentrations due to CoA sequestration (e.g., 
upon exposure to xenobiotics and drugs [5]). 
4.2.2.3. Regulatory non-coding RNAs 
As peroxisomes play a central role in cellular redox metabolism [5], and Dicer, a 
cytoplasmic ribonuclease III that processes pre-miRs to mature miRs, functions as an 
oxidative stress-responsive protein [7] - it is very likely that changes in peroxisome 
function also influence the biogenesis and processing of miRs. Experimental evidence 
that this may actually be the case has recently emerged. For example, it has been shown 
that enhanced catalase activity can attenuate the H2O2-induced upregulation of miR-
153 in SH-SY5Y neuroblastoma cells [48]. MiR-153 targets, among others, the redox-
sensitive transcription factor nuclear factor-erythroid 2-related factor 2 (NFE2L2), a 
master regulator of antioxidant transcriptional responses [48]. In addition, it has been 
demonstrated that the expression of several miRs is upregulated in PEX16-deficient 
human skin fibroblasts, and that peroxisomal dysfunction stimulates apoptotic cell 
death of articular chondrocytes and cartilage degradation in osteoarthritis patients and 
mice with type 2 diabetes through upregulation of miR-223 [49]. Finally, changes in 
Dicer activity also affect peroxisome function; this is perhaps best illustrated by the 
observation that inactivation of Dicer in mouse liver results in the upregulation of 
peroxisome proliferator-activated receptor (PPAR) alpha target proteins (e.g., 
peroxisomal -oxidation enzymes) [50]. 
5. Peroxisomes and the cellular microenvironment 
Peroxisomes are remarkably versatile and dynamic cell organelles whose size, shape, 
number, and protein content can vary greatly depending on cell type, developmental 
state, and environment [51]. Here we elaborate on microenvironmental factors that can 
modulate peroxisome biogenesis and function (Fig. 2). Gaining a better understanding 
of this relationship is a prerequisite for designing safe and effective therapeutic 
interventions (see 6.). 
5.1. Nutrient availability and xenobiotic stimuli 
It is well documented that cells can quickly adapt peroxisome number and function in 
response to changes in nutrient conditions and xenobiotic stimuli. Many of these 
adaptations are mediated through activation of PPAR-dependent signaling pathways. 
PPARs are a group of transcription factors (PPARα, PPAR, and PPAR) that 
constitute a subfamily of the nuclear receptor superfamily and function as lipid sensors 
and regulators of (lipid) metabolism (see [4], and references therein). All PPAR 
isoforms function as obligate heterodimers with retinoid X receptor (RXR), a nuclear 
receptor that is activated by 9-cis-retinoic acid, to regulate downstream target gene 
expression upon activation by their agonists. Important classes of PPAR agonists 
include, among others, naturally occurring fatty acids, fibrates, and thiazolidinediones. 
PPARs show distinct tissue distribution patterns and have pleiotropic effects on a wide 
range of cellular processes, including peroxisome biogenesis. For example, fatty acid 
and fibrate activation of PPARα stimulates peroxisome formation (e.g., through 
enhanced expression of PEX11, a protein involved in peroxisome proliferation) and 
fatty acid -oxidation in various tissues [51]. Also, treatment of murine 3T3-L1 pre-
adipocyte cells with rosiglitazone, a potent thiazolidinedione insulin sensitizer, induces 
the expression of several PEX genes through activation of PPAR [4]; and high fat 
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feeding increases PPAR expression and the proliferation of peroxisomes in the 
hypothalamus [52]. Finally, a cardiomyocyte-specific loss of PPAR in mice results in 
reduced expression of peroxisomal and mitochondrial β-oxidation genes and leads to 
cardiomyopathy [53]. Note that the extent to which these and other PPAR-mediated 
processes are influenced is not only species-dependent [51], but can also be affected by 
the availability of specific transcriptional coactivators, such as PPARGC1A [54]. 
The complex interplay between peroxisomes, PPARs, and epigenetic regulation 
mechanisms is further strengthened by additional important observations. For example, 
it has been demonstrated that butyrate-producing probiotics (e.g. 4-phenylbutyrate) can 
upregulate peroxisome activity through inactivation of HDAC activity (see 2.2.2.), an 
event that enhances the expression of PPAR [55]. Also, it has been reported that PPAR 
levels can be controlled by miRs whose expression levels are affected by oxygen 
tension [56] or inflammatory stimuli [57]. Regarding the latter, it is important to note 
that (i) peroxisomal β-oxidation is also involved in the breakdown of eicosanoids, a 
class of bioactive lipid mediators that can elicit a broad range of inflammatory reactions 
[3], and (ii) impairment of peroxisome function can contribute significantly to the 
prolongation and intensification of inflammatory reactions [23]. These and other 
findings have led to the idea that even mild peroxisome biogenesis defects (e.g., caused 
by a deficiency in PEX11) may lead to an accumulation (e.g., VLCFAs, eicosanoids) 
and/or depletion (e.g., polyunsaturated fatty acids, alkyl ether-phospholipids) of PPAR 
ligands, thereby deregulating PPAR activity and peroxisome/PPAR-feedback loops 
[58]. 
5.2. Oxidative stress 
Over the years, it has become evident that alterations in the cellular redox balance can 
influence peroxisome biogenesis and function at various levels. In the following 
paragraphs, we provide a set of examples of how oxidative stress may regulate these 
processes at the transcriptional, post-transcriptional, and post-translational level. Note 
that most of these examples focus on the expression, subcellular localization, and 
activity of catalase, the best characterized peroxisomal antioxidant enzyme. 
First, it has been reported that catalase is downregulated in many patient and mouse 
tumor tissues, and that this phenomenon can be mimicked in cellulo by exposing 
hepatocellular carcinoma cells to ROS [59,60]. A molecular analysis of these cells 
revealed that ROS treatment resulted in epigenetic silencing of catalase through 
hypermethylation of CpG island II on the catalase promoter [59] and methylation of 
CpG island in the POU2F1 promoter [60]. Note that POU2F1 is a transcription factor 
that binds to the promoter of catalase to upregulate its expression. 
Second, catalase activity can also be regulated at the post-transcriptional level via miR 
expression. For example, sublethal doses of H2O2 have been shown to upregulate the 
expression of miR-30b, a small ncRNA that inhibits the expression of catalase in human 
retinal pigment epithelial cells [61]. In addition, it has been reported that receptor-
interacting protein 1, a key mediator in cell survival and death signaling, blunts the 
anticancer activity of cisplatin by decreasing the expression of miR-146a, another small 
ncRNA that represses catalase expression [62]. 
Lastly, catalase activity can also be influenced at the post-translational level by S-
nitrosylation and oxidative stress-induced changes in subcellular localization [5]. How 
S-nitrosylation influences catalase activity remains to be investigated. Regarding the 
observation that oxidative stress can affect catalase localization, it is important to point 
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out that peroxisome biogenesis and function become gradually impaired as cells age 
[63]. Indeed, Terlecky and co-workers have shown that cellular aging, a process 
associated with an increase in oxidative stress, is accompanied with (i) a decrease in the 
import of proteins containing a C-terminal peroxisomal targeting signal (PTS1), (ii) an 
accumulation of PEX5, the shuttling import receptor for PTS1 proteins, on the 
peroxisomal membrane, and (iii) an increase in peroxisome number. These phenomena 
may very well be explained by the fact that PEX5 functions as a redox-sensitive protein, 
a property that can be attributed to an evolutionarily conserved cysteine residue (e.g., 
Cys11 in human PEX5) that is involved in receptor monoubiquitination [64]. As this 
monoubiquitination event marks PEX5 for recycling [64] and can potentially also serve 
as a quality control mechanism to eliminate peroxisomes with a defective protein import 
machinery [65], the increased redox balance of the cytosol in aging cells can be 
expected to impair matrix protein import and, possibly also, peroxisome degradation 
pathways. Interestingly, as (i) the extent of mislocalization of individual PTS1 proteins 
apparently depends on the strength of the targeting signal, and (ii) catalase, in contrast 
to most peroxisomal H2O2-producing oxidases, contains a relatively weak PTS1, the 
existence of a self-perpetuating negative protein import spiral causing oxidative stress 
and peroxisome dysfunction has been postulated [66]. However, as the 
monoubiquitinable cysteine residue in the N-terminus of PEX5 and the weak PTS1 of 
catalase are highly conserved in virtually all mammalian species, these features may 
also have evolved to allow cells to rapidly respond to oxidative insults in the cytosol 
[64]. The latter idea is supported by the observation that valosin-containing protein, an 
ATPase associated with diverse cellular activities, can sense and regulate H2O2 levels 
in the cytosol by affecting the retention time of (newly-synthesized) catalase within this 
cellular compartment [67]. 
5.3. Oxygen tension 
Oxygen is a key intermediate and critical signaling molecule for multiple cellular 
processes. As changes in oxygen concentration can contribute to cell dysfunction, cells 
have evolved mechanisms to rapidly sense and respond to changes in oxygen tension 
in their microenvironment. One such mechanism involves the action of hypoxia-
inducible factors (HIFs), a class of transcriptional regulators of genes that mediate 
cellular adaptation to hypoxia [68]. 
As peroxisomal flavin oxidases consume molecular oxygen (see 4.1.1.), it can be 
expected that changes in oxygen tension also affect peroxisome function. That this is 
indeed the case is supported by findings in which peroxisome volume and catalase 
activity are two- and four-fold increased, respectively, in hyperoxia (99% O2, 1% CO2)-
adapted Chinese hamster ovary cells, as compared to parental cells that are cultivated 
at normoxic conditions (20% O2, 1% CO2, 79% N2) [69]. In addition, it has been 
reported that, under hypoxic conditions (<2% O2, 5% CO2, balanced N2), peroxisome 
number and function are upregulated in human glioblastoma cells [70] but strongly 
reduced in human skin fibroblasts [71]. Note that the increase in peroxisome activity in 
hypoxic glioblastoma cells has been linked to enhanced expression and increased 
nuclear localization of PPARα [70]. Finally, it has recently been demonstrated that 
EPAS1 (HIF2A) functions as a negative regulator of peroxisome abundance and 
metabolism in mouse hepatocytes and human clear cell renal cell carcinomas [72]. This 
observation led these authors to hypothesize that the hypoxia-driven expression of 




More than a decade ago, it was reported that culturing fibroblast cell lines from PBD 
patients with an intermediate (e.g., NALD) or milder (e.g., IRD) phenotype (see 4.2.1.) 
at lower temperature frequently resulted in the rescue of peroxisome biogenesis errors 
and functional defects [73]. This finding suggested that mutations in the respective PEX 
genes (e.g., PEX1, PEX2, PEX5, PEX6, or PEX13) yield structurally unstable proteins, 
hinting that chemical or pharmacological chaperones may restore biological function 
and serve as a strategy for therapeutic treatment (see 6.5.). In addition, these outcomes 
suggested that precautions to prevent fever may be necessary as part of treatment 
regimen of PBD patients with temperature-sensitive mutations [73]. Finally, with an 
eye toward predictive analyses, an examination of the temperature sensitivity of 
peroxisome biogenesis in fibroblasts of newborns may help to assess the severity of, 
and identify a prognosis for, patients with peroxisome disease [73]. 
6. Therapeutic Interventions 
Peroxisomal disorders comprise a family of genetically heterogeneous and progressive 
diseases that display a broad phenotypic spectrum [7,35]. At present, effective 
treatments are still limited and not universally applicable due to the complex nature of 
these disorders. For example, in patients with severe ZSD, treatment is mainly 
symptomatic and supportive [7]. Fortunately, most patients with milder symptoms have 
defects that retain residual protein function, raising the possibility that specific 
treatments may enhance protein activity (e.g., through upregulation or stabilization of 
the affected protein) or mitigate downstream metabolic perturbations (e.g., the lack of 
plasmalogens, the accumulation of VLCFAs, and mitochondrial dysfunction). In the 
following sections, we discuss therapies that have already been explored or are 
currently in development to treat patients suffering from peroxisomal disorders (Fig. 
3). Note that we will only focus on treatments that act directly at the level of the 
epigenome, and not on surgical procedures (e.g., haematopoietic stem cell or bone 
marrow transplantation) that have already proven to halt disease progression (e.g., in 
early-stage cerebral ALD) [74]. 
6.1. Diet therapies 
Strategies to mitigate the symptoms of peroxisomal disorders often include dietary 
changes. These can include supplementation of missing metabolites (e.g., primary bile 
acids, docosahexaenoic acid (DHA), and plasmalogen precursors), dietary restrictions 
of metabolites that accumulate (e.g., phytanic acid), or diet treatments that normalize 
biochemical parameters (e.g., VLCFA levels). 
6.1.1. Lorenzo’s oil 
The perhaps best-known diet therapy for peroxisomal disorders is “Lorenzo’s oil”, a 
4:1 mixture of glyceryl trioleate and glyceryl trierucate. In combination with a moderate 
reduction of fat in the diet, this therapy has been shown to significantly lower the levels 
of VLCFAs in plasma of X-ALD and ZS patients (see [74], and references therein). 
Currently, this process is thought to occur through inhibition of ELOVL1, a fatty acid 
elongase responsible for the synthesis of saturated and monounsaturated VLCFAs [75]. 
Unfortunately, Lorenzo’s oil appears to be ineffective in halting or preventing the 
neurological decline in cerebral variants of X-ALD [74]. However, a combination 
therapy of Lorenzo’s oil, DHA (see below), and medium-chain triglyceride milk can 
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apparently alleviate liver damage, muscle weakness, and neurological deficits in a ZS 
patient [76]. 
6.1.2. DHA 
Interestingly, a clinical study evaluating the efficacy of DHA in ZSD patients 
demonstrated that supplementation of DHA ethyl ester restored blood DHA values 
within a few weeks [77]. In addition, this work showed that such treatment also 
normalized various biochemical (e.g., VLCFAs and plasmalogen levels, brain myelin) 
and clinical (e.g., vision, liver function, muscle tone, social contact) parameters in 
several patients. ZS model mice, when treated with DHA, do not show overall 
improvements, despite the normalization of DHA levels in the brain [78]. 
6.1.3. Plasmalogen precursors 
One group of peroxisomal disorders, which include the RCDP patients, is characterized 
by a failure in plasmalogen biosynthesis [79]. As peroxisomes are only necessary for 
the initial biosynthesis steps of this unique class of molecules, it should, in principle, 
be possible to recover plasmalogen levels in RCDP (and ZSD) patients by oral 
supplementation of plasmalogen precursors (e.g., 1-0-octadecyl-sn-glycerol) that can 
enter the plasmalogen biosynthetic pathway downstream of the peroxisomal steps. This 
idea is supported by the observations that 1-0-octadecyl-sn-glycerol supplementation 
significantly increased plasmalogen levels in erythrocytes from ZSD patients (see [79], 
and references therein) as well as in erythrocytes and multiple peripheral organs (e.g., 
liver, kidney, heart, lung, testis, and the eye) of PEX7-deficient mice [80]. Interestingly, 
when administered prior to the realization of major pathological changes, plasmalogen 
replacement therapy also halted or slowed the development of pathology normally 
observed in Pex7 knockout mice (e.g., testicular degeneration and cataract formation) 
[80].Unfortunately, the 1-0-octadecyl-sn-glycerol-containing diet could only 
marginally increase plasmalogen levels in nervous tissues; how this diet affects the 
lifespan of these mice is unknown at present [80]. 
6.1.4. Primary bile acids 
The final steps of bile acid synthesis occur in peroxisomes, and defects in peroxisome 
assembly have been shown to lead to an increase of C27, and a decrease of C24 bile 
acids [3]. Studies in Pex2-/- ZS mice have demonstrated that feeding these mice a 
solution containing cholic acid and ursodeoxycholic acid improved bile acid deficiency 
in bile and liver [81]. In addition, although mitochondrial alterations persisted, this 
treatment prolonged postnatal survival. In the meantime, the United States Food and 
Drug Administration has recently approved cholic acid capsules (Cholbam) to treat 
adults and children with bile acid synthesis disorders, including ZSDs; this is the first 
and only drug of its kind (see 
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm438572.htm). 
6.2. Peroxisome proliferators 
Peroxisome proliferators are a group of structurally diverse molecules that function as 
agonists of PPARs (see 5.1.), thereby affecting a large network of cellular activities, 
ranging from (peroxisomal) metabolism and inflammation, to cellular differentiation 
and development [4,82]. Common pharmaceutical applications include fibrates (e.g., 
fenofibrate and bezafibrate) and thiazolidinediones (e.g., rosiglitazone and 
pioglitazone) - established therapeutics for hypercholesterolemia and type 2 diabetes, 
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respectively. While these drugs may not be beneficial for ZSD patients where the 
organelle is completely absent, they may be of value in more modest forms of 
peroxisome disease. For instance, there is much evidence to argue that fibrates can 
restore VLCFA -oxidation in X-ALD fibroblasts as well as in the liver of Abcd1-/- 
mice (see [83], and references therein). However, the mechanisms underlying this 
phenomenon appear to be complex and diverse (see continued discussion in next 
paragraph). In addition, there is some evidence that PPAR agonists such as 
rosiglitazone and pioglitazone can protect hypothalamic pro-opiomelanocortin neurons 
[52] and cortical neurons [84] from inflammatory mediators via an improvement in 
peroxisome function. 
To understand how fibrates may lower VLCFA levels in various cell types and tissues, 
it is essential to know that (i) mammalian peroxisomes contain three ABCD proteins 
(ABCD1/ALDP, ABCD2/ALDPR, and ABCD3/PMP70), each displaying substantial 
overlap in function; (ii) overexpression of ABCD2 or ABCD3 can rescue peroxisomal 
β-oxidation in X-ALD fibroblasts; and (iii) fibrate therapy stimulates ABCD2 and 
ABCD3 expression in a PPAR-dependent manner in rodent liver and adrenal glands, 
but not in brain and testis (see [74], and references therein). Despite the latter 
observation, a detailed analysis of the promoter region of the ABCD2 gene failed to 
identify functional peroxisome proliferator response elements, suggesting that the 
PPAR-dependent activation of this gene may occur through an indirect mechanism 
[74]. Evidence in favor of such a conclusion was provided by experiments showing that 
the mouse and human ABCD2 promoters contain DNA sequences that are recognized 
by sterol regulatory element (SRE)-binding proteins (SREBPs), a group of transcription 
factors whose expression depends on PPAR activity [74]. Importantly, CoA esters of 
different fibrates (e.g., bezafibrate and gemfibrozil) have also been shown to reduce 
VLCFA accumulation in X-ALD fibroblasts by directly inhibiting the fatty acid 
elongase activity of ELOVL1 [83,85]. 
As PPARs are involved in a wide array of metabolic processes, it is logical that 
treatment with these compounds could cause many undesirable side effects. PPAR 
agonists such as clofibrate and fenofibrate have been approved for use in humans and 
are generally considered safe, however there is a concern that the molecules may be 
acting as nongenotoxic carcinogens – a circumstance certainly true in rodents. 
6.3. HDAC activity modulators 
HDACs are established and validated targets for the treatment of many diseases, 
ranging from metabolic and inflammatory disorders to neurodegeneration and cancer. 
A growing body of evidence has accumulated that suggests patients with peroxisomal 
defects, especially those with defects in ABCD1, may benefit from treatment with 
agents that modulate HDAC activity. Promising molecules include, among others, the 
class I and II HDAC inhibitors 4-phenylbutyrate (4-PBA) and suberoylanilide 
hydroxamic acid (SAHA), and the putative class III HDAC activator resveratrol. 
4-PBA, an FDA-approved HDAC inhibitor for the treatment of urea cycle disorders, 
has been shown to significantly increase the number of peroxisomes, the expression of 
ABCD2, and VLCFA β-oxidation in cells from X-ALD patients and Abcd1-/- mice (see 
[74], and references therein). In addition, this compound upregulates the transcription 
of ABCD2 and PEX11 in fibroblasts from ZSD patients, to restore peroxisomal β-
oxidation and plasmalogen content in cells from NALD and IRD (but not ZS) patients, 
and to increase the number of peroxisomes and the expression of peroxisomal genes 
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(e.g., ABCD2) in rat liver as well as in primary rat hepatocytes and glial cell cultures 
(see [74], and references therein). Interestingly, the latter study also demonstrated that 
the dose-dependent increase in ABCD2 expression required the recruitment of HDAC1, 
but not PPAR, to the ABCD2 promoter. Note that 4-PBE also has documented 
chemical chaperone activity (see 6.5.). 
SAHA, an FDA-approved HDAC inhibitor for the treatment of cutaneous T-cell 
lymphoma, has been shown to lower VLCFAs in the central nervous system of Abcd1-
/- mice, the target tissue in human X-ALD pathology [86]. In addition, in X-ALD 
fibroblasts, the compound increases the expression levels of ABCD2 and ABCD3, 
normalizes peroxisomal β-oxidation, and downregulates the expression of ELOVL1 
[86]. Interestingly, a recent study reported that SAHA attenuates mitochondrial 
dysfunction and energetic failure in ABCD1-silenced human U87 astrocytes and rat B12 
oligodendrocytes through PPARGC1A- and PPARGC1B-induced mitochondrial 
biogenesis [87]. These findings also reinforce the view that intact peroxisomes are 
essential to maintain mitochondrial integrity and function. 
Resveratrol is a dietary phytophenol that exerts its biological activity via a number of 
mechanisms that may vary depending on cell type, dose, and dosing schedule [88]. 
Cellular processes shown to be affected by this compound include, among others, 
metabolism, inflammation, cell signaling, and posttranslational modification. However, 
resveratrol’s pharmacological mode of action is not yet fully understood, and many 
potential targets (e.g., histone deacetylase inhibition, AMP-activated protein kinase 
activation, and miRNA modulation) have been proposed [88]. It was recently 
demonstrated that oral administration of resveratrol could normalize redox 
homeostasis, mitochondrial respiration, bioenergetic failure, and axonal degradation 
and associated locomotor disabilities in Abcd1-/- mice [43]. In addition, as (i) SIRT1 
activity was impaired in the spinal cord of Abcd1-/- mice as well as in the affected white 
matter of X-ALD patients, and (ii) a moderate transgenic overexpression of SIRT1 in 
Abcd1-/- mice yielded similar beneficial effects, the authors concluded that the 
resveratrol-dependent health benefits are mediated via activation of SIRT1. Whether 
resveratrol activates SIRT1 directly or indirectly, remains to be investigated. In this 
context, it is interesting to note that this compound has been shown to directly inhibit 
cAMP-specific phosphodiesterases [89]. This in turn triggers the activation of AMP-
activated protein kinase, a metabolic sensor that enhances SIRT1 activity by increasing 
the intracellular NAD+ levels. In addition, resveratrol may also influence the expression 
of various miRs [90]. 
In summary, these findings suggest that HDAC activity modulators such as 4-PBA and 
SAHA are potential therapeutics for treatment of X-ALD. However, whether or not 
these compounds will be of any benefit in the context of peroxisomal disorders is 
unclear. This is perhaps best illustrated by the fact that, despite 4-PBA’s ability to 
upregulate peroxisome number and VLCFA β-oxidation in various cell types and 
tissues (see above), a trial in adrenomyeloneuropathy patients failed to demonstrate any 
clinical efficacy [74]. 
6.4. Antioxidants 
Currently, there is ample evidence that peroxisome biogenesis, peroxisome function, 
and maintenance of cellular redox balance are intricately connected processes [23]. This 
is nicely illustrated by the observations that peroxisome biogenesis and function decline 
during cellular aging, a process associated with oxidative stress, and that catalase-SKL 
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(a catalase derivative with enhanced peroxisome targeting) and N-acetylcysteine (a 
thiol-reducing agent and precursor of GSH) can restore peroxisomal protein import and 
normal oxidative state in aging cells [63,64,91]. Interestingly, N-acetylcysteine has also 
been shown (i) to attenuate peroxisome dysfunction (e.g., β-oxidation, plasmalogen 
biosynthesis) and oxidative stress in a PPAR-dependent manner in fetal mouse brain 
upon exposure of the mothers to lipopolysaccharides, a major constituent of the outer 
membrane of Gram-negative bacteria and primary inducer of chronic inflammatory 
diseases and septic shock [92], and (ii) to scavenge VLCFA-dependent ROS generation 
in human X-ALD fibroblasts [93]. Importantly, the latter study also demonstrated that 
the oral administration of an antioxidant cocktail consisting of N-acetylcysteine, lipoic 
acid, and Trolox (a water-soluble analog of vitamin E) could block oxidative damage 
to proteins and DNA in the spinal cord from Abcd1-/- mice and prevent and arrest 
progression of locomotor deficits in Abcd1-/-/Abcd2-/- mice. Taken together, these 
findings open new perspectives for the use of antioxidant cocktails for patient treatment. 
A clinical trial on the use of antioxidants to slow progression of 
adrenomyeloneuropathy (NCT01495260) has recently been completed but, to date, the 
results obtained have not been published. 
6.5. Chemical chaperones 
A relatively unstudied intervention includes the use of chemical chaperones, a group of 
small osmolytes (e.g., betaine, glycerol, trimethylamine N-oxide, L-proline, L-arginine) 
and hydrophobic compounds (e.g., 4-PBA, bile acids) that assist in the proper folding 
of proteins: osmolytes increase the stability of proteins without affecting their activity 
through sequestration of water molecules, an event that increases the free energy of the 
protein’s unfolded state more than its folded state; and hydrophobic compounds prevent 
protein aggregation by shielding exposed hydrophobic segments of unfolded proteins 
[94]. The chemical chaperones trimethylamine N-oxide, glycerol, betaine, and L-
proline have been shown to partially recover matrix protein import in primary 
fibroblasts from a mildly-affected ZSD patient containing the common disease allele 
PEX1-p.Gly843Asp (G843D), a mutation that causes a conformational change and 
renders the protein inactive [95]. Another study reported that supplementation of L-
arginine to the cell culture medium can improve peroxisome biogenesis and function in 
human fibroblasts with mild missense mutations in PEX1, PEX6, and PEX12 [96]. 
Betaine is also currently being evaluated in a clinical trial (NCT01838941) that is 
intended to test whether or not it can restore key peroxisome functions (e.g., VLCFA 
and bile acid profiles, plasmalogen levels) in the blood of PEX1-G843D patients.  
6.6. Nonsense suppressors 
Nonsense suppressors enable tRNA to bypass stop-codons and continue translation. 
Popular examples include the aminoglycoside antibiotics gentamicin and geneticin 
(G418). A few years ago, it was reported that addition of G418 to the cell culture 
medium could partially rescue peroxisome biogenesis and significantly improve 
peroxisomal lipid metabolism in ZSD skin fibroblasts from patients with stable PEX2 
or PEX12 nonsense transcripts [97]. These findings support the idea that nonsense 
suppressor therapies may be beneficial for a subset of ZSD patients. 
6.7. Enzyme replacement therapy 
Enzyme replacement therapy (ERT) is a potentially attractive medical treatment 
approach in which proteins are administered to patients to compensate for the loss of a 
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particular enzyme that is dysfunctional or absent. Over the years, ERT has been 
successfully employed in such systemic diseases as hemophilia and lysosomal storage 
disorders, in which intravenously administered enzymes can easily reach therapeutic 
levels in relevant target organs [98]. However, development and characterization of 
short peptides that promote the cellular uptake of specific cargo molecules, have 
broadened the spectrum of disorders that are potentially targets for ERT. Catalase-SKL 
is one such cell penetrating peptide-containing protein biologic; importantly, it has been 
shown to protect primary rat cortical/hippocampal neurons from amyloid-β-induced 
toxicity [99] and to correct oxidative stress-induced pathophysiology in incipient 
diabetic retinopathy [100]. As patients with peroxisomal diseases experience 
neurodegeneration [7], these studies not only reinforce the idea that antioxidants can be 
part of effective therapeutic strategies (see 6.4.), but also underscore the powerful 
potential of ERT in dealing with ZSDs and PEDs. 
7. Conclusions and perspectives 
Peroxisomes are linked to the epigenetic landscape in ways only beginning to be 
understood. A plethora of compelling evidence points to the importance of such 
bidirectional crosstalk between the systems, but a clear mechanistic understanding of 
this cellular relationship remains elusive. Contributing to the complexity are the 
following: (i) the activity of many enzymes involved in epigenetic regulation is subject 
to exquisite regulation by metabolite concentrations (see 3.); (ii) the intracellular levels 
of many of these metabolites are controlled by peroxisomal as well as mitochondrial 
metabolism (see 4.1.); (iii) the cause and effect relationships between peroxisomal 
(dys)function and epigenetic alterations are clearly modulated by a number of complex 
feedforward/feedback mechanisms (see 5.); and (iv) the cellular epigenetic landscape 
and its bidirectional relationship with peroxisomes and associated organelle function 
can differ significantly among cell types, tissues, organs, organisms, and disease states. 
These complexities are relevant to the development of therapeutic strategies designed 
to thwart peroxisomal disease; what is effective in one patient, may not be in another. 
However, the new information outlined in this review, including the only recently 
described revelation that peroxisomes are highly druggable targets, provides hope that 
a door has opened for unparalleled rapid advancement in the development of 
compounds and strategies to combat the devastating circumstance that is human 
peroxisomal disease. 
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Fig. 1. Peroxisomal metabolites have the potential to influence the epigenetic 
landscape. Molecules that can be linked to peroxisomal metabolism are shown in blue. 
The arrows and the bars represent stimulatory and inhibitory signals, respectively. 
Multiple arrows represent a series of enzymatic steps not described in the text. -KG, 
α-ketoglutarate; acetyl-CoA, acetyl-coenzyme A; DDM, DNA demethylase; DNMT, 
DNA methyltransferase; FAD(H2), (reduced) flavin adenine dinucleotide; GR, 
glutathione reductase; GSH, (reduced) glutathione; GSSG, oxidized glutathione; HAT, 
histone acetylase; HDAC, histone deacetylase; HDM, histone demethylase; HMT, 
histone methyltransferase; NAD(P)(H), (reduced) nicotinamide adenine dinucleotide 
(phosphate); ncRNA, non-coding RNA; PARG, poly(ADP-ribose) glycohydrolase; 
PARP, poly(ADP-ribose) polymerase; SAH, S-adenosylhomocysteine; SAM, S-
adenosylmethionine. 
Fig. 2. Influence of genetic and environmental factors on peroxisome biogenesis and 
function. 
Fig. 3. Potential epigenetic therapies to treat peroxisomal disease. 4-PBA, 4-
phenylbutyrate; BA, bile acid; CC, chemical chaperone; DHA, docosahexaenoic acid; 
ERT, enzyme replacement therapy; HDAC, histone deacetylase; NAC, N-
acetylcysteine; NS, nonsense; PP, plasmalogen precursor; SAHA, suberoylanilide 
hydroxamic acid. 
